Latest news with #EPSgrowth
Yahoo
31-07-2025
- Business
- Yahoo
BBR Holdings (S)'s (SGX:KJ5) investors will be pleased with their notable 95% return over the last year
If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boost your returns by picking above-average stocks. To wit, the BBR Holdings (S) Ltd (SGX:KJ5) share price is 90% higher than it was a year ago, much better than the market return of around 22% (not including dividends) in the same period. So that should have shareholders smiling. It is also impressive that the stock is up 76% over three years, adding to the sense that it is a real winner. Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During the last year BBR Holdings (S) grew its earnings per share (EPS) by 231%. It's fair to say that the share price gain of 90% did not keep pace with the EPS growth. So it seems like the market has cooled on BBR Holdings (S), despite the growth. Interesting. This cautious sentiment is reflected in its (fairly low) P/E ratio of 3.28. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). It might be well worthwhile taking a look at our free report on BBR Holdings (S)'s earnings, revenue and cash flow. What About Dividends? As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for BBR Holdings (S) the TSR over the last 1 year was 95%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return. A Different Perspective It's nice to see that BBR Holdings (S) shareholders have received a total shareholder return of 95% over the last year. And that does include the dividend. That's better than the annualised return of 8% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for BBR Holdings (S) you should know about. But note: BBR Holdings (S) may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Singaporean exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-07-2025
- Business
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
26-07-2025
- Business
- Yahoo
Should You Be Adding Korvest (ASX:KOV) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should. In contrast to all that, many investors prefer to focus on companies like Korvest (ASX:KOV), which has not only revenues, but also profits. While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. How Fast Is Korvest Growing? If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. That makes EPS growth an attractive quality for any company. We can see that in the last three years Korvest grew its EPS by 4.2% per year. This may not be setting the world alight, but it does show that EPS is on the upwards trend. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. EBIT margins for Korvest remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 17% to AU$120m. That's progress. The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers. View our latest analysis for Korvest Korvest isn't a huge company, given its market capitalisation of AU$141m. That makes it extra important to check on its balance sheet strength. Are Korvest Insiders Aligned With All Shareholders? It's said that there's no smoke without fire. For investors, insider buying is often the smoke that indicates which stocks could set the market alight. That's because insider buying often indicates that those closest to the company have confidence that the share price will perform well. Of course, we can never be sure what insiders are thinking, we can only judge their actions. We haven't seen any insiders selling Korvest shares, in the last year. With that in mind, it's heartening that Warrick R. Ranson, the Independent Non-Executive Director of the company, paid AU$25k for shares at around AU$9.93 each. It seems that at least one insider is prepared to show the market there is potential within Korvest. Should You Add Korvest To Your Watchlist? As previously touched on, Korvest is a growing business, which is encouraging. Not every business can grow its EPS, but Korvest certainly can. Despite there being a solitary insider adding to their holdings, it's enough to consider adding this to the watchlist. Even so, be aware that Korvest is showing 2 warning signs in our investment analysis , you should know about... There are plenty of other companies that have insiders buying up shares. So if you like the sound of Korvest, you'll probably love this curated collection of companies in AU that have an attractive valuation alongside insider buying in the last three months. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-07-2025
- Business
- Yahoo
If EPS Growth Is Important To You, TSH (Catalist:KUH) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up. So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like TSH (Catalist:KUH). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. TSH's Earnings Per Share Are Growing If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. TSH's shareholders have have plenty to be happy about as their annual EPS growth for the last 3 years was 54%. Growth that fast may well be fleeting, but it should be more than enough to pique the interest of the wary stock pickers. It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. TSH shareholders can take confidence from the fact that EBIT margins are up from 5.9% to 8.4%, and revenue is growing. Both of which are great metrics to check off for potential growth. In the chart below, you can see how the company has grown earnings and revenue, over time. For finer detail, click on the image. View our latest analysis for TSH Since TSH is no giant, with a market capitalisation of S$4.3m, you should definitely check its cash and debt before getting too excited about its prospects. Are TSH Insiders Aligned With All Shareholders? Theory would suggest that it's an encouraging sign to see high insider ownership of a company, since it ties company performance directly to the financial success of its management. So we're pleased to report that TSH insiders own a meaningful share of the business. To be exact, company insiders hold 80% of the company, so their decisions have a significant impact on their investments. This makes it apparent they will be incentivised to plan for the long term - a positive for shareholders with a sit and hold strategy. Valued at only S$4.3m TSH is really small for a listed company. So despite a large proportional holding, insiders only have S$3.4m worth of stock. That's not a huge stake in absolute terms, but it should help keep insiders aligned with other shareholders. It means a lot to see insiders invested in the business, but shareholders may be wondering if remuneration policies are in their best interest. Our quick analysis into CEO remuneration would seem to indicate they are. Our analysis has discovered that the median total compensation for the CEOs of companies like TSH with market caps under S$257m is about S$479k. TSH offered total compensation worth S$331k to its CEO in the year to December 2024. That is actually below the median for CEO's of similarly sized companies. CEO compensation is hardly the most important aspect of a company to consider, but when it's reasonable, that gives a little more confidence that leadership are looking out for shareholder interests. It can also be a sign of a culture of integrity, in a broader sense. Is TSH Worth Keeping An Eye On? TSH's earnings per share growth have been climbing higher at an appreciable rate. An added bonus for those interested is that management hold a heap of stock and the CEO pay is quite reasonable, illustrating good cash management. The sharp increase in earnings could signal good business momentum. Big growth can make big winners, so the writing on the wall tells us that TSH is worth considering carefully. You still need to take note of risks, for example - TSH has 2 warning signs we think you should be aware of. Although TSH certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of Singaporean companies that not only boast of strong growth but have strong insider backing. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-07-2025
- Business
- Yahoo
Food Empire Holdings (SGX:F03) stock performs better than its underlying earnings growth over last three years
For us, stock picking is in large part the hunt for the truly magnificent stocks. Not every pick can be a winner, but when you pick the right stock, you can win big. For example, the Food Empire Holdings Limited (SGX:F03) share price is up a whopping 366% in the last three years, a handsome return for long term holders. On top of that, the share price is up 66% in about a quarter. Since it's been a strong week for Food Empire Holdings shareholders, let's have a look at trend of the longer term fundamentals. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. Food Empire Holdings was able to grow its EPS at 40% per year over three years, sending the share price higher. This EPS growth is lower than the 67% average annual increase in the share price. This suggests that, as the business progressed over the last few years, it gained the confidence of market participants. It is quite common to see investors become enamoured with a business, after a few years of solid progress. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). We know that Food Empire Holdings has improved its bottom line over the last three years, but what does the future have in store? Take a more thorough look at Food Empire Holdings' financial health with this free report on its balance sheet. What About Dividends? When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for Food Empire Holdings the TSR over the last 3 years was 459%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! A Different Perspective We're pleased to report that Food Empire Holdings shareholders have received a total shareholder return of 136% over one year. Of course, that includes the dividend. That gain is better than the annual TSR over five years, which is 41%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 2 warning signs for Food Empire Holdings (1 is potentially serious!) that you should be aware of before investing here. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Singaporean exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
